Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chih-Lin Lin

Showing results (101-110 of 132) with videos related to

Pageof 14
Sort By:
Molecular Carcinogenesis|September 11, 2020
Longitudinal change of metabolite profile and its relation to multiple risk factors for the risk of developing hepatitis B-related hepatocellular carcinomaBo-Yuan Huang, Min-Ru Tsai, Jia-Kai Hsu, et al.
Scientific Reports|July 2, 2015
Peginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: a randomized trialChen-Hua Liu, Chung-Feng Huang, Chun-Jen Liu, et al.
Scientific Reports|October 16, 2015
Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized TrialChen-Hua Liu, Chung-Feng Huang, Chun-Jen Liu, et al.
Journal of Hepatology|October 5, 2024
Risk of de novo HCC in patients with MASLD following direct-acting antiviral-induced cure of HCV infectionChen-Hua Liu, Pin-Nan Cheng, Yu-Jen Fang, et al.
Journal of Gastroenterology and Hepatology|April 2, 2019
Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysisChen-Hua Liu, Yu-Lueng Shih, Sheng-Shun Yang, et al.
Alimentary Pharmacology & Therapeutics|February 21, 2025
Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral-Induced Cure of Hepatitis C Virus InfectionYu-Ping Chang, Ji-Yuh Lee, Chi-Yi Chen, et al.
Journal of Medical Virology|May 15, 2024
Four weeks of off-treatment follow-up is sufficient to determine virologic responses at off-treatment week 12 in patients with hepatitis C virus infection receiving fixed-dose pangenotypic direct-acting antiviralsChen-Hua Liu, Yu-Ping Chang, Ji-Yuh Lee, et al.
Journal of Gastroenterology|April 13, 2024
Dynamic change of metabolic dysfunction-associated steatotic liver disease in patients with hepatitis C virus infection after achieving sustained virologic response with direct-acting antiviralsChen-Hua Liu, Yu-Ping Chang, Yu-Jen Fang, et al.
Journal of Gastroenterology and Hepatology|November 14, 2025
Predictive Value of Serum Mac-2 Binding Protein Glycosylation Isomer for Hepatic Fibrosis in Hepatitis C Virus-Infected Patients With Metabolic Dysfunction-Associated Steatotic Liver DiseaseYun-Chu Chen, Yu-Ping Chang, Ji-Yuh Lee, et al.
Journal of Medical Virology|January 15, 2026
Effect of Glycated Hemoglobin Levels on Serum Mac-2 Binding Protein Glycosylation Isomer in the Diagnosis of Hepatitis C-Virus Related Hepatic FibrosisYu-Ping Chang, Yun-Chu Chen, Ji-Yuh Lee, et al.
Pageof 14

Showing results (101-110 of 132) with videos related to

Sort By:
Pageof 14
Molecular Carcinogenesis|September 11, 2020
Longitudinal change of metabolite profile and its relation to multiple risk factors for the risk of developing hepatitis B-related hepatocellular carcinomaBo-Yuan Huang, Min-Ru Tsai, Jia-Kai Hsu, et al.
Scientific Reports|July 2, 2015
Peginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: a randomized trialChen-Hua Liu, Chung-Feng Huang, Chun-Jen Liu, et al.
Scientific Reports|October 16, 2015
Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized TrialChen-Hua Liu, Chung-Feng Huang, Chun-Jen Liu, et al.
Journal of Hepatology|October 5, 2024
Risk of de novo HCC in patients with MASLD following direct-acting antiviral-induced cure of HCV infectionChen-Hua Liu, Pin-Nan Cheng, Yu-Jen Fang, et al.
Journal of Gastroenterology and Hepatology|April 2, 2019
Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysisChen-Hua Liu, Yu-Lueng Shih, Sheng-Shun Yang, et al.
Alimentary Pharmacology & Therapeutics|February 21, 2025
Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral-Induced Cure of Hepatitis C Virus InfectionYu-Ping Chang, Ji-Yuh Lee, Chi-Yi Chen, et al.
Journal of Medical Virology|May 15, 2024
Four weeks of off-treatment follow-up is sufficient to determine virologic responses at off-treatment week 12 in patients with hepatitis C virus infection receiving fixed-dose pangenotypic direct-acting antiviralsChen-Hua Liu, Yu-Ping Chang, Ji-Yuh Lee, et al.
Journal of Gastroenterology|April 13, 2024
Dynamic change of metabolic dysfunction-associated steatotic liver disease in patients with hepatitis C virus infection after achieving sustained virologic response with direct-acting antiviralsChen-Hua Liu, Yu-Ping Chang, Yu-Jen Fang, et al.
Journal of Gastroenterology and Hepatology|November 14, 2025
Predictive Value of Serum Mac-2 Binding Protein Glycosylation Isomer for Hepatic Fibrosis in Hepatitis C Virus-Infected Patients With Metabolic Dysfunction-Associated Steatotic Liver DiseaseYun-Chu Chen, Yu-Ping Chang, Ji-Yuh Lee, et al.
Journal of Medical Virology|January 15, 2026
Effect of Glycated Hemoglobin Levels on Serum Mac-2 Binding Protein Glycosylation Isomer in the Diagnosis of Hepatitis C-Virus Related Hepatic FibrosisYu-Ping Chang, Yun-Chu Chen, Ji-Yuh Lee, et al.
Pageof 14